Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study

• DOI: 10.1111/jch.14969
• Publication Date: 2025-01-18T17:50:03Z
• Authors: Yu Yan; Xiaomin Li; Juan Cao; Jingyuan Cao; Yao Wang; Liang Wang; Jirong Yu; Lianhua Chen; Min Yang; Xinzhong Huang; Lei Shen; Hong Ding; Manzhi Li; Di Yin; Linglin Jiang; Liang Tang; Yujia Jiang; Ling Hu; Jiyi Si; Hui Zhang; Liqin Cui; Xiameng Gu; Kun Hu; Dongxing Mu; Bicheng Liu; Xiaoliang Zhang; Dong Sun; Xin Wan; Bin Wang
• Keywords: Sacubitril, Valsartan

To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure individuals with non-dialysis-dependent chronic kidney disease (NDD-CKD) Stage 3-5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to 31, 2024, involving adult patients NDD-CKD hypertension, who received either as monotherapy or addition current antihypertensive treatments that were insufficient. The main outcomes measured control, changes laboratory parameters within 8 weeks post-treatment initiation, incidence adverse events. included total 459 At endpoint, mean systolic pressure, diastolic pulse markedly reduced compared baseline (all p < 0.001). average reductions 12.17 (4.66, 22.00), 6.00 (0.67, 12.66), 6.67 (0.08, 14.00) mmHg, respectively. Throughout period, 96 (20.92%) developed worsening renal function, 15 (3.27%) hyperkalemia, 49 (10.68%) experienced symptomatic hypotension. Overall, there no significant differences serum creatinine, estimated glomerular filtration rate, potassium before after treatment (p = 0.28, 0.91, 0.61, respectively). significantly lowers good profiles. Trial Registration: ClinicalTrials.gov identifier: ChiCTR2400086079.